Cephalon/Cima Merger Contingent On Granting Generic Actiq License To Barr
This article was originally published in The Pink Sheet Daily
Executive Summary
Barr's generic version of Actiq would enter the market when FDA approves Cima's fentanyl product, but no later than February 2007. The companies expect the merger to close in the next few days.